| Biomarker ID | 1191 |
| PMID | 23918943 |
| Year | 2013 |
| Biomarker | Methylation Status of HAPLN3 (as continous variable) |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Hypermethylated in Prostate Cancer |
| Odds Ratio/Hazard Ratio/Relative Risk | Cohort 1: univariate : [HR = 1.617 (95% CI: 1.051-2.487), p-value = 0.029] |
| Effect on Pathways | Pathways include: PASK human kinase ARCHS4 coexpression, PIM2 human kinase ARCHS4 coexpression, RIPK1 human kinase ARCHS4 coexpression, PRKX human kinase ARCHS4 coexpression, TESK2 human kinase ARCHS4 coexpression |
| Experiment | Biochemical recurrence |
| Type of Biomarker | Prognostic |
| Cohort | Nonmalignant samples [(adjacent normal [ADJ-N], benign prostatic hyperplasia (BPH)( n = 35)] and radical prostatectomy (RP) samples (n = 293) were chosen for the study |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.928 |
| Accuracy | NA |
| Level Of Significance | P < 0.001 |
| Method Used | quantitative methylation specific PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | HAPLN3 |